Biology subjects

Liang, Y.-L.

Publications and source records attributed to Liang, Y.-L..

7 recordsLinked to original sources

bioRxiv2026

Synora: vector-based boundary detection for spatial omics

Tumor-stroma boundaries are critical microenvironmental niches where malignant and non-malignant cells exchange signals that shape invasion, immune modulation and therapeutic response. Spatial omics platforms now resolve these interfaces at single-cell scale, but computational boundary detection remains challenging because heterogeneous neighborhoods can arise either from true compartment interfaces or from unstructured immune infiltration. Here we present Synora, a modality-agnostic computational framework that identifies tumor boundaries using only cell coordinates and binary tumor/non-tumor annotations, making it readily applicable across a broad range of spatial omics modalities. Synora introduces orientedness, a novel metric that quantifies directional neighborhood asymmetry and distinguishes true boundary cells, where neighbors are spatially segregated by type, from infiltrated regions where cell types intermingle randomly. By integrating orientedness with traditional diversity measures into a unified BoundaryScore, Synora achieves robust boundary identification across synthetic datasets with ground-truth boundaries, maintaining performance under realistic perturbations including 50% missing cells and 25% infiltration. Application to 15 Visium HD spatial transcriptomic datasets across multiple cancer types reveals consistent boundary-enriched gene signatures and cell-type spatial gradients. Validation on a CODEX multiplexed protein dataset demonstrates that Synoras precise boundary identification enables discovery of clinically relevant cellular neighborhoods and disease-associated spatial patterns missed by frequency-based approaches. Synora enables boundary-aware spatial analyses by making tissue interfaces quantifiable from minimal inputs, helping to standardize interface detection and comparison across spatial omics platforms and biological contexts.

bioinformatics↗

bioRxiv2022

Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics

Allosteric modulation of G protein-coupled receptors (GPCRs) is a major paradigm in drug discovery. Despite decades of research, a molecular level understanding of the general principals that govern the myriad pharmacological effects exerted by GPCR allosteric modulators remains limited. The M4 muscarinic acetylcholine receptor (M4 mAChR) is a well-validated and clinically relevant allosteric drug target for several major psychiatric and cognitive disorders. Here, we present high-resolution cryo-electron microscopy structures of the M4 mAChR bound to a cognate Gi1 protein and the high affinity agonist, iperoxo, in the absence and presence of two different positive allosteric modulators, LY2033298 or VU0467154. We have also determined the structure of the M4 mAChR-Gi1 complex bound to its endogenous agonist, acetylcholine (ACh). Structural comparisons, together with molecular dynamics, mutagenesis, and pharmacological validations, have provided in-depth insights into the role of structure and dynamics in orthosteric and allosteric ligand binding, global mechanisms of receptor activation, cooperativity, probe-dependence, and species variability; all key hallmarks underpinning contemporary GPCR drug discovery.

pharmacology and toxicology↗

bioRxiv2021

Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation

The glucagon-like peptide-1 receptor (GLP-1R) has broad physiological roles and is a validated target for treatment of metabolic disorders. Despite recent advances in GLP-1R structure elucidation, detailed mechanistic understanding of how different peptides generate profound differences in G protein-mediated signalling is still lacking. Here we have combined cryo-electron microscopy, molecular dynamics simulations, receptor mutagenesis and pharmacological assays, to interrogate the mechanism and consequences of GLP-1R binding by four peptide agonists; glucagon-like peptide-1, oxyntomodulin, exendin-4 and exendin-P5. These data revealed that distinctions in peptide N-terminal interactions and dynamics with the GLP-1R transmembrane domain are reciprocally associated with differences in the allosteric coupling to G proteins. In particular, transient interactions with residues at the base of the binding cavity correlate with enhanced kinetics for G protein activation, providing a rationale for differences in G protein-mediated signalling efficacy from distinct agonists.

biochemistry↗

bioRxiv2021

Structure and dynamics of semaglutide and taspoglutide bound GLP-1R-Gs complexes

The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, carbohydrate metabolism and appetite, and is an important target for treatment of type II diabetes and obesity. Multiple GLP-1R agonists have entered into clinical trials, such as semaglutide, progressing to approval. Others, including taspoglutide, failed through high incidence of side-effects or insufficient efficacy. GLP-1R agonists have a broad spectrum of signalling profiles. However, molecular understanding is limited by a lack of structural information on how different GLP-1R agonists engage with the GLP-1R. In this study, we determined cryo-electron microscopy (cryo-EM) structures of GLP-1R-Gs protein complexes bound with semaglutide and taspoglutide. These revealed similar peptide binding modes to that previously observed for GLP-1. However, 3D variability analysis of the cryo-EM micrographs revealed different motions within the bound peptides and the receptor relative to when GLP-1 is bound. This work provides novel insights into the molecular determinants of peptide engagement with the GLP-1R.

biochemistry↗

bioRxiv2020

Routine sub-2.5 A cryo-EM structure determination of B-family G protein-coupled receptors

Cryo-electron microscopy (cryo-EM) experienced game-changing hardware and software advances about a decade ago. Since then, there have been gradual and steady improvements in experimental and data analysis methods. Nonetheless, structural analysis of nonsymmetric membrane proteins, such as G protein-coupled receptors (GPCRs), remains challenging. Their relatively low molecular weight and obstruction by the micelle/nanodisc result in marginal signal levels, which combined with the intrinsic flexibility of such complexes creates difficult structural study scenarios. Pushing the performance limits of cryo-EM requires careful optimization of all experimental aspects. To this end, it is necessary to build quantitative knowledge of the effect each parameter has on the outcome. Here, we present in-depth analysis of the influence of the main cryo-EM experimental factors on the performance for GPCR structure determination. We used a tandem experiment approach that combined real-world structural studies with parameter testing. We quantified the effects of using a Volta phase plate, zero-loss energy filtering, objective lens aperture, defocus magnitude, total exposure, and grid type. Through such systematic optimization of the experimental conditions, it has been possible to routinely determine class B1 GPCR structures at resolutions better than 2.5 [A]. The improved fidelity of such maps helps to build higher confidence atomic models and will be crucial for the future expansion of cryo-EM into the structure-based drug design domain. The optimization guidelines drafted here are not limited to GPCRs and can be applied directly for the study of other challenging membrane protein targets.

biophysics↗

bioRxiv2020

Differential GLP-1R binding and activation by peptide and non-peptide agonists

Peptide drugs targeting class B1 GPCRs can treat multiple diseases, however there remains substantial interest in the development of orally delivered non-peptide drugs. Here we reveal unexpected overlap between signalling and regulation of the glucagon-like peptide-1 (GLP-1) receptor by the non-peptide agonist, PF 06882961, and GLP-1 that was not observed for another compound, OWL-833. Both compounds are currently in clinical trials for treatment of type 2 diabetes. High resolution cryo-EM structures reveal the binding sites for PF-06882961 and GLP-1 substantially overlap, whereas OWL-833 adopts a unique binding mode with a more open receptor conformation at the extracellular face. Structural differences involving extensive water-mediated hydrogen bond networks could be correlated to functional data to understand how PF 06882961, but not OWL-833, can closely mimic the pharmacological properties of GLP-1. These findings will facilitate rational structure-based discovery of non-peptide agonists targeting class B GPCRs.

pharmacology and toxicology↗

bioRxiv2020

Lnc-ECAL-1 controls cerebrovascular homeostasis by targeting endothelium-specific tight junction protein Cldn5b

Cerebrovascular disorder-induced brain blood flow interruption or intracranial hemorrhage pose a great threaten to health. Emerging roles of long-noncoding RNAs (lncRNAs) in diagnosis and treatment of cardiovascular diseases have been recognized. However, whether and how lncRNAs modulate vascular homeostasis, especially network formation remain largely unknown. Here, we identified ECAL-1, a long non-coding RNA, as an important determinant for cerebrovascular homeostasis. Using the morpholino- and CRISPR /Cas9-based genetic modifications in combination with in vivo confocal imaging in zebrafish, we claimed that inactivation of ECAL-1 induced the apparent distortion of cerebral vascular pattern accompanied by intracranial hemorrhage. These cerebrovascular abnormalities were associated with decreased proliferation and anomalous interconnection of endothelial cells. Importantly, overexpression of Cldn5b, an endothelial cell-specific tight junction protein-encoding gene, could partially rescued the phenotype induced by ECAL-1 deficiency. Furthermore, bioinformatic analysis and experimental validation revealed that ECAL-1 sponged miR-23a, which targeted Cldn5b 3UTR and modulated Cldn5b expression, to maintain cerebrovascular pattern formation and integrity. Our results presented here revealed that ECAL-1 specifically controls cerebrovascular network formation and integrity through targeting miR-23a-Cldn5b axis. These findings provide a new regulation modality for cerebrovascular patterning and the potential neurovascular disorders, and ECAL-1-miR-23a axis represents as an attractive therapeutic target for cerebrovascular diseases.

developmental biology↗